Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 47Lung Neoplasms 43Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 26Multiple Myeloma 24Glioma 22Pancreatic Neoplasms 21Carcinoma, Renal Cell 21Lymphoma, Large B-Cell, Diffuse 20Ovarian Neoplasms 19Melanoma 19Glioblastoma 19Squamous Cell Carcinoma of Head and Neck 18Lymphoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Triple Negative Breast Neoplasms 14Brain Neoplasms 14Fallopian Tube Neoplasms 13Carcinoma 13Laryngeal Neoplasms 12Carcinoma, Hepatocellular 12Astrocytoma 12Leukemia, Myeloid, Acute 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10

Interventions

cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡